The minimal inhibitory concentration for sulbactam was not associated with the outcome of infections caused by carbapenem-resistant Acinetobacter sp. treated with ampicillin/sulbactam
Clinics
;
68(4): 569-573, abr. 2013. graf
Article
Dans Anglais
| LILACS
| ID: lil-674232
ABSTRACT
OBJECTIVE:
The objective of this study was to evaluate whether the outcomes of carbapenem-resistant Acinetobacter infections treated with ampicillin/sulbactam were associated with the in vitro susceptibility profiles.METHODS:
Twenty-two infections were treated with ampicillin/sulbactam. The median treatment duration was 14 days (range 3-19 days), and the median daily dose was 9 g (range 1.5-12 g). The median time between Acinetobacter isolation and treatment was 4 days (range 0-11 days).RESULTS:
The sulbactam minimal inhibitory concentration (MIC) ranged from 2.0 to 32.0 mg/L, and the MIC was not associated with patient outcome, as 4 of 5 (80%) patients with a resistant infection (MIC≥16), 5 of 10 (50%) patients with intermediate isolates (MIC of 8) and only 1 of 7 (14%) patients with susceptible isolates (MIC ≤4) survived hospitalization.CONCLUSION:
These findings highlight the need to improve the correlation between in vitro susceptibility tests and clinical outcome. .
Texte intégral:
Disponible
Indice:
LILAS (Amériques)
Sujet Principal:
Acinetobacter
/
Infections à Acinetobacter
/
Sulbactam
/
Ampicilline
/
Antibactériens
Type d'étude:
Études d'évaluation
/
Facteurs de risque
Limites du sujet:
Adolescent
/
Adulte
/
Adulte très âgé
/
Aged80
/
Enfant
/
Femelle
/
Humains
/
Mâle
langue:
Anglais
Texte intégral:
Clinics
Thème du journal:
Médicament
Année:
2013
Type:
Article
Pays d'affiliation:
Brésil
Institution/Pays d'affiliation:
Universidade de São Paulo/BR
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS